Navigation Links
New polysaccharide may help combat multidrug resistance in cancer

In a recent study published in the Journal of Biological Chemistry, scientists report that a molecule previously thought to play a purely structural and inert role in cells is actually involved in multidrug resistance in cancer. Using antagonists for this molecule, the researchers were able to sensitize drug resistant breast cancer cells to chemotherapeutic drug treatment.

The research appears as the "Paper of the Week" in the May 27 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

Multidrug resistance is very common in most types of cancers, making it one of the leading problems in cancer therapy. It is often caused by an increase in the cell's production of proteins that transport drugs out of the cell, preventing the drugs from combating cancer.

Previously, Dr. Bryan P. Toole and his coworkers, Drs. Suniti Misra and Shibnath Ghatak, of the Medical University of South Carolina noticed that small pieces, or oligomers, of a polysaccharide called hyaluronan were able to sensitize drug-resistant breast cancer cells to several different chemotherapeutic drugs. He believed that the polysaccharide oligomers were binding to a receptor for hyaluronan (called CD44) and preventing it from initiating a signaling cascade that would result in drug resistance.

"It is very surprising that hyaluronan is involved in drug resistance," admits Dr. Toole. "Most scientists think of hyaluronan as a structural and inert molecule. In adult tissues it plays two roles. First, it assists in tissue hydration and in biophysical properties such as resilience. Second, it forms a template to which matrix proteins attach and form important extracellular structural complexes."

Hyaluronan also accumulates around the outside of cells during disease processes such as early atherogenesis, persistent inflammation, and cancer. In recent years, however, hyaluronan has also been shown to induce signaling pathways in inflammatory, embryonic and cancer cells.

In their current Journal of Biological Chemistry paper, Dr. Toole and his colleagues report on further studies which indicate that hyaluronan increases the cellular production of a multidrug transporter protein by binding to CD44. They discovered that antagonist molecules that bind to hyaluronan and prevent it from interacting with CD44 were able to sensitize multidrug resistant breast cancer cells to chemotherapeutic drugs. The researchers also found that increasing hyaluronan synthesis in cells increased resistance to drug treatment.

"Our work indicates that hyaluronan antagonists, for example small hyaluronan oligomers, reverse the malignant properties of cancer cells, including proliferation, invasiveness, and drug resistance," explains Dr. Toole. "Hyaluronan oligomers are non-toxic, non-immunogenic, and readily applicable to several proliferative disease processes, especially cancer. We are hoping that hyaluronan antagonists can be used in conjunction with chemotherapy such that much lower and less toxic doses of chemotherapeutic agents can be used."


'"/>

Source:American Society for Biochemistry and Molecular Biology


Related biology news :

1. Molecular machine may lead to new drugs to combat human diseases
2. A bacterial genome reveals new targets to combat infectious disease
3. Light therapy may combat fungal infections, new evidence suggests
4. AIDS expert says global strategy needed to combat feminization of HIV/AIDS
5. Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases
6. Storing carbon to combat global warming may cause other environmental problems, study suggests
7. New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics
8. Asleep in the deep: Model helps assess ocean-injection strategy for combating greenhouse effect
9. Pair of studies offer new clues to combat antibiotic resistance
10. Team discovers possible universal strategy to combat addiction
11. Retinol for combating leukemia cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced today that they have entered into a multiyear collaboration to identify and ... researchers with additional tools for gene editing across all applications. , Under the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalindâ„¢, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
Breaking Biology Technology: